Covington & Burling advised Selecta Biosciences, Inc. on the transaction, and Foley Hoag advised Cartesian Therapeutics. Selecta Biosciences (Nasdaq:SELB) (“Selecta”) announced its merger with Cartesian Therapeutics and concurrent...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Roivant Sciences Ltd. in the deal, while Covington represented the underwriter, Cantor Fitzgerald. Roivant Sciences Ltd. announced its debut SEC-registered offering of 30,000,000...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Immatics on the offering while Covington represented underwriters. Immatics N.V. executed its $110 million SEC-registered offering of ordinary shares. The ordinary shares are...
You must be a Standard 1 Year member to access this content.
Covington & Burling advised Ceptur Therapeutics on the deal. Ceptur Therapeutics, Inc., a biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology,...
You must be a Standard 1 Year member to access this content.
